| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443867 | European Journal of Cancer | 2013 | 8 Pages |
Abstract
Sorafenib and bevacizumab combination showed clinical benefit but unfavourable safety results compared with drugs in monotherapy. Further development of this combination is not warranted and a sequential approach is recommended instead.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Daniel Castellano, Jaume Capdevila, Javier Sastre, Vicente Alonso, Marta Llanos, RocÃo GarcÃa-Carbonero, José Luis Manzano Mozo, Isabel Sevilla, Ignacio Durán, Ramón Salazar,